Why the study?
Does NT-proBNP serve as an early marker for acute anthracycline cardiotoxicity in pediatric cancer patients?
Population
23 consecutive pediatric patients with newly diagnosed cancer receiving anthracycline-containing…
Comparison
Anthracycline-containing chemotherapy vs Age-matched controls and baseline measurements
Design
Cohort
Follow-up
End of anthracycline treatment courses
Authors
Loading...
Acute NT-proBNP rise after first anthracycline dose lacks immediate echo correlate in children; leaves open its utility as an early cardiotoxicity marker.
Does NT-proBNP serve as an early marker for acute anthracycline cardiotoxicity in pediatric cancer patients?
NT-proBNP increases significantly after the first anthracycline course in pediatric cancer patients, but this acute rise is not associated with immediate clinical or echocardiographic cardiac dysfunction.
Ekstein et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: